While PhRMA says it has been a longtime proponent for boosting affordability and predictability of cost-sharing in Medicare Part D, it says the Senate Finance Committee’s latest package is the wrong course of action.
PhRMA in a blog post says the committee “has pushed for changes that would upend Part D without any immediate and meaningful savings for most patients at the pharmacy counter.”
The post highlights three key reasons why PhRMA believes the package is the wrong move.
“The Senate Finance package would fundamentally alter how parts of Medicare and Medicaid covers beneficiaries and would siphon more than $120 billion from researching and developing new medicines,” the post states.
To read the full post oh PhRMA’s website, click here.